Tracked deals
4
4 tracked deals across 2021-2026.
Public Company
Healthcare
Charles River Laboratories
Wilmington, Massachusetts, United States
Global provider of products and services to accelerate pharmaceutical and biotechnology research, including preclinical/clinical laboratory and contract development and manufacturing services.
- Focus Areas
- Preclinical and clinical laboratory services, Contract development and manufacturing services (CDMO), Cell and gene therapy CDMO and CGMP manufacturing capabilities
- Website
- criver.com
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Buyout
4 buyout
Charles River Laboratories Acquisition Volume by Year
Last 3 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
January 13, 2026
- Buyer
- Charles River Laboratories International
- Target
- K.F. (Cambodia) Ltd., PathoQuest SAS
- Industry
- Healthcare Services
- Location
- Cambodia
- Type
- Buyout
Charles River Laboratories International agreed to acquire K.F. (Cambodia) Ltd. for about $510 million and to purchase the remaining 79% of PathoQuest SAS for €51.6 million, bringing the combined deal value to roughly $570 million. Charles River expects both transactions to close in the first quarter of 2026 (with PathoQuest by end of Q1 2026).
-
January 30, 2023
- Buyer
- Charles River Laboratories International, Inc.
- Target
- SAMDI Tech, Inc.
- Industry
- Biotechnology
- Location
- Illinois, United States
- Type
- Buyout
Charles River Laboratories acquired the remaining 80% stake in SAMDI Tech for $50 million in cash, completing a transaction that follows a partnership begun in 2018. The acquisition integrates SAMDI Tech's proprietary mass spectrometry high-throughput screening technology into Charles River's Discovery and Safety Assessment segment to strengthen drug discovery capabilities and accelerate hit identification for pharmaceutical and biotech clients.
-
- Buyer
- Charles River Laboratories International, Inc.
- Target
- Vigene Biosciences, Inc.
- Seller
- Signet Healthcare Partners
- Industry
- Biotechnology
- Location
- Maryland, United States
- Type
- Buyout
Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.
-
February 17, 2021
- Buyer
- Charles River Laboratories International, Inc.
- Target
- Cognate BioServices, Inc.
- Seller
- EW Healthcare Partners, Medivate Partners, BlackRock, Unnamed sovereign wealth fund
- Industry
- Biotechnology
- Location
- Tennessee, United States
- Type
- Buyout
Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
3 tracked deals by Charles River Laboratories.
Healthcare Services Buyers & Acquisitions
1 tracked deal by Charles River Laboratories.
Acquisitions in Illinois
1 tracked deal by Charles River Laboratories.
Acquisitions in Maryland
1 tracked deal by Charles River Laboratories.
Acquisitions in Tennessee
1 tracked deal by Charles River Laboratories.
Selling a company? Get in front of buyers like Charles River Laboratories
Turn tracked acquisition activity into an outreach-ready buyer list.